On June 15, NCHC’s John Rother collaborated with Katy Spangler, the Co-Director of Smarter Health Care Coalition, and Dr. A. Mark Fendrick, the Director of the University of Michigan Center for Value-Based Insurance Design, to publish an article in The Hill about high-value care amidst COVID-19. COVID-19 has created unprecedented opportunities for change, including the […]
Here, you will find all mentions of NCHC in the news from 2017-present. Please see here for all 2016 and previous media mentions.
You can read the published op-ed on The Hill here. Future prescription drug costs are projected to spike to unsustainable levels. Biologic pharmaceuticals will make up the majority of new drugs, and unfortunately, they are commonly priced at over five figures for a course of treatment. These drugs promise new breakthroughs in treatments for patients with certain […]
By NOAM N. LEVEY and JENNIFER HABERKORN In a much-anticipated piece of political theater, seven leading pharmaceutical executives appeared before a powerful Senate committee Tuesday for a grilling from lawmakers who pledged a historic bipartisan effort to rein in skyrocketing prescription drug prices. But even as drug prices have emerged as one of the few areas of common […]
The original letter to the editor was published on January 15, 2018 and can be found here. The article in which the letter responds to can be found here. By John Rother The U.S. is alone among developed nations in failing to assure more affordable medications for its citizens. Medicare trustees have an obligation to act prudently to obtain fair prices for beneficiaries. Recent research has […]
By John Rother & David Introcaso Originally posted on Morning Consult. You can read the original op-ed here. Americans are forced to spend over $1 trillion annually on health care services that do not improve their health. What causes this is not the amount of health care services we consume. Compared to similar countries, the […]